Alvotech
Every calculator, already run for ALVO
Open the full toolkit →You have the numbers on ALVO. Get the argument.
A written report on which of these readings actually decide the outcome for Alvotech, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering ALVOAnalyst Price Target Disagreement for Alvotech
Wall Street's bull case implies +53% from the current price; the bear case implies -32%. A 85% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ALVO
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosi…
ALVO — frequently asked
Is ALVO a buy right now?
Wall Street's consensus rating on Alvotech is Buy across 7 analysts, with a mean price target of $6.80 (+16% vs. the current $5.87). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ALVO's next earnings date?
Alvotech is next scheduled to report earnings around Nov 11, 2026. A full ALVO research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Alvotech?
Analysts covering Alvotech (ALVO) range from a bear-case target of $4.00 to a bull-case high of $9.00, with a mean consensus target of $6.80 across 5 analysts. The spread of $5.00 (85% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Alvotech against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Alvotech
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ALVO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Alvotech, in minutes. 3 free reports included with every account — no credit card required.